Compare Recursion Pharmaceuticals Inc (RXRX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sibanye Stillwater Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $3.25 (market cap $1.86B), while Sibanye Stillwater Ltd trades at $13.14 (market cap $9.35B). The key difference: Sibanye Stillwater Ltd is far larger — about 5× Recursion Pharmaceuticals Inc's market cap, and Sibanye Stillwater Ltd pays a 6.27% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SBSW | |
|---|---|---|
Market Cap | $1.86B | $9.35B |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $21.12 |
52-Week Low | $2.84 | $8.00 |
Enterprise Value | $1.38B | $10.29B |
Dividend Yield | — | 6.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
SBSW trades at $12.90, up 0.86% today, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26, and the company reported a strong turnaround in operating cash flow to $21.41 billion in 2025. Valuation ratios appear attractive with a P/E of 10.2 and EV/EBITDA of 5.2, while analyst consensus is a Buy with a $14.00 price target.
The outlook is positive due to robust earnings performance and improving cash flows, but risks include volatile commodity prices and high debt levels. Investment opportunity lies in potential upside to the consensus target, supported by operational momentum and disciplined capital allocation plans highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
